/
ABVX
$132.07+$35.92 (+37.36%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.8B
80M shares
52-week range
$7.41 – $148.83
88% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$123.77
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.0K | $2.0K | $63.0K | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $15.4M | $28.2M | $33.8M | $45.5M | $50.8M | $0 | $0 | $0 |
| Gross profit | −$15.4M | −$28.2M | −$33.8M | −$45.5M | −$50.8M | $0 | $0 | $0 |
| Gross margin | -85327.8% | -1409300.0% | -53623.8% | — | — | — | — | — |
| R&D | $0 | $0 | $0 | $47.8M | $48.3M | $103.2M | $146.5M | $177.8M |
| Operating income | −$19.1M | −$33.3M | −$38.0M | −$41.4M | −$64.8M | −$127.4M | −$173.0M | −$246.1M |
| EBITDA | −$19.2M | −$33.2M | −$38.0M | −$38.6M | −$53.3M | −$133.2M | −$162.7M | −$300.7M |
| Net income | −$15.8M | −$30.6M | −$37.6M | −$42.5M | −$60.7M | −$147.7M | −$176.2M | −$336.1M |
| Net margin | -87905.6% | -1531700.0% | -59604.8% | — | — | — | — | — |
| EPS (diluted) | -1.55 | -2.51 | -2.62 | -2.75 | -3.18 | -3.43 | -2.80 | -4.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $71M | $-2.56 | $-3.13–$-2.24 | 5 |
| 2027 | $115M | $-3.09 | $-3.37–$-2.79 | 4 |
| 2028 | $457M | $-0.23 | $-0.55–$0.05 | 4 |
| 2029 | $1.1B | $4.85 | $4.60–$5.22 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.29
Price
$132.07
Implied downside
-94%
Peer comparison
Abivax SA American Depositary Shares
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
www.abivax.com- Employees
- 69
- IPO / List date
- Oct 20, 2023
Held by traders on TradeandTell
No one on the platform currently holds ABVX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ABVX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ABVX yet.
